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introduction: The optimal prostate stereotactic body radiation therapy (SBRT)
dose-fractionation scheme is controversial. This study compares long-term quality of life 
(QOL) from two prospective trials of prostate SBRT to investigate the effect of increasing 
dose (NCT01578902 and NCT01146340).
Material and methods: Patients with localized prostate cancer received SBRT 35 or 
40 Gy delivered in five fractions, once per week. QOL was measured using the Expanded 
Prostate Cancer Index Composite at baseline and every 6 months. Fisher’s exact test 
and generalized estimating equations were used to analyze proportions of patients with 
clinically significant change and longitudinal changes in QOL.
results: One hundred fourteen patients were included, 84 treated with 35 Gy and 30 
treated with 40  Gy. Median QOL follow-up was 56  months [interquartile range (IQR) 
46–60] and 38 months (IQR 32–42), respectively. The proportion of patients reporting 
clinically significant declines in average urinary, bowel, and sexual scores were not 
significantly different between dose levels, and were 20.5 vs. 24.1% (p = 0.60), 26.8 
vs. 41.4% (p = 0.16), and 42.9 vs. 38.5% (p = 0.82), respectively. Similarly, longitudinal 
analysis did not identify significant differences in QOL between treatment groups.
Conclusion: Dose-escalated prostate SBRT from 35 to 40 Gy in five fractions was not 
associated with significant decline in long-term QOL.
 
Keywords: prostatic neoplasms, stereotactic body radiotherapy, radiotherapy, quality of life, clinical trial, radiation 
effects
Abbreviations: ADT, androgen deprivation therapy; CTV, clinical target volume; Dmax, maximum dose; EORTC, European 
Organization for Research and Treatment of Cancer; EPIC, Expanded Prostate Cancer Index Composite; GI, gastrointestinal; 
GU, genitourinary; HR, hazard ratio; IMRT, intensity-modulated radiotherapy; IPSS, International Prostate Symptom Score; 
IQR, interquartile range; MCIC, minimum clinically important change; OAR, organs at risk; ProCaRS, prostate cancer risk 
stratification; PSA = prostate-specific antigen; PTV, planning target volume; QOL, quality of life; RTOG, Radiation Therapy 
Oncology Group; SBRT, stereotactic body radiation therapy.
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inTrODUCTiOn
There has been significant interest in stereotactic body radia-
tion therapy (SBRT) for prostate cancer, given the potential for 
increased tumor control (1), patient convenience, and lower 
treatment costs (2). However, the optimal dose and fractionation 
remain controversial, with total doses ranging from 33.5 to 50 Gy 
delivered in five fractions (3–5).
No randomized studies have been conducted to evaluate the 
impact of dose-escalated prostate SBRT. In the only prospective 
dose-escalation SBRT study to date, groups of 15 patients received 
45, 47.5, and 50 Gy in five fractions (5). Grade 3+ toxicities were 
limited to one patient treated with 47.5  Gy and two patients 
who received 50 Gy. Bowel quality of life (QOL) was worse for 
patients on the 47.5 Gy arm, but no differences were found in 
urinary QOL.
Quality-of-life outcomes have become increasingly important 
in patient counseling as patient-reported experiences can be dis-
cordant from physician-rated toxicities (6). There is limited data 
examining QOL outcomes with increasing prostate SBRT dose. 
Therefore, we conducted a comparative analysis of long-term 
QOL outcomes from two prospective clinical trials to evaluate the 
impact of increasing prostate SBRT dose from 35 to 40 Gy in five 
fractions. Analysis of biochemical control and toxicity outcomes 
has been reported separately (7).
MaTErialS anD METHODS
This study is a secondary analysis of data from two prospective 
clinical trials (NCT01578902 and NCT01146340). Both trials 
were approved by the research ethics board at Sunnybrook Health 
Sciences Centre. Informed consent was provided by all patients.
Study 1
Treatment details of study 1 have been previously published 
(3, 8). Men over 18 years of age with prostate adenocarcinoma 
and clinical stage T1-T2b (TNM 2002), Gleason sum ≤6, and 
Prostate-specific antigen (PSA)  ≤  10  ng/mL were eligible. 
Neoadjuvant androgen deprivation therapy (ADT) was permit-
ted. Patients were excluded if they had received prior pelvic 
radiotherapy, a bleeding diathesis, which precluded gold fiducial 
marker insertion, hip prosthesis, pelvic girth >  40  cm, pros-
tate > 90 cm3 on imaging, or International Prostate Symptom 
Score (IPSS) > 19.
Patients received 35  Gy in five fractions delivered once per 
week over 29 days. Each patient underwent transperineal inser-
tion of three gold fiducial markers followed by CT simulation. 
Patients were immobilized in a vacuum lock bag (Vac-Lock, 
MED-TEC Inc., Orange City, IA, USA) with a comfortably full 
bladder and empty rectum for simulation and treatment.
The clinical target volume (CTV) consisted of the prostate 
only. Organs at risk (OAR) were contoured as solid organs and 
included the rectum, bladder, penile bulb, and femoral heads. 
The planning target volume (PTV) included the CTV plus an 
isotropic 4 mm margin. Planning objectives included the volume 
of CTV receiving 35 Gy (CTV V35 Gy) to receive >99%, PTV 
V33.25  Gy >  99%, PTV maximum dose (Dmax) ≤  36.75  Gy. 
Normal tissue constraints were rectum V28 Gy  ≤  40%, V32 
Gy ≤ 33%, bladder V32 Gy ≤ 40%, and penile bulb V20 ≤ 90%.
Patients were treated on linear accelerators (Siemens Primus, 
Concord, CA, USA; Elekta Synergy, Stockhold, Sweden) using 
a “step-and-shoot” intensity-modulated radiotherapy (IMRT) 
technique with 6 MV photons. Daily image-guidance was per-
formed using orthogonal portal images to identify the fiducial 
markers and apply any necessary table shifts before treatment.
Study 2
The second study included men over 18 years of age with prostate 
adenocarcinoma and clinical stage T1-2b, Gleason sum ≤ 6, and 
PSA ≤ 15 ng/mL; or clinical T1-2b, Gleason 7, and PSA ≤ 10 ng/
mL. Neoadjuvant ADT was also permitted. Exclusion criteria 
were the same as for study 1.
Patients received 40  Gy in five fractions delivered once per 
week over 29  days. Patients underwent multiparametric MRI 
using cardiac surface coil with gadolinium infusion. After the MRI 
(to reduce artifacts), three gold fiducial markers were inserted 
transperineally. Patients, then, underwent CT simulation up to 
1 week later. Immobilization and bladder and bowel filling were 
the same as for study 1. CT simulation images were fused with 
MRI for target delineation.
The CTV consisted of the prostate only and OAR were the same 
as for study 1. The PTV included the CTV and an isotropic 5 mm 
margin. Planning objectives included a CTV V40 Gy >  99%, 
PTV V38 Gy >  99%, and PTV Dmax ≤  42  Gy. Normal tissue 
constraints were rectum V28 Gy ≤ 20% (up to maximum 40%), 
V31.8 Gy ≤ 15% (up to maximum 33%), bladder V31.8 Gy ≤ 15% 
(up to maximum 40%), and penile bulb V20 ≤ 90% (maximum 
V22.2 Gy < 90%). Patients were treated on the same machines 
using the same image-guidance protocol as for study 1.
Patient assessments
Quality of life was assessed using the Expanded Prostate Cancer 
Index Composite (EPIC) (9), a validated 50-item instrument 
that measures prostate cancer-specific QOL. It consists of four 
summary domains (urinary, bowel, sexual, and hormonal) with 
function and bother subscales for each domain. Scores were 
transformed to a 0–100 scale, with higher scores indicating 
better QOL.
Day 0 was defined as the start of radiotherapy. QOL was 
assessed at baseline and every 6  months thereafter. In study 2, 
QOL was also assessed at week 5 and month 3. Because QOL was 
not assessed during the acute time period in study 1, QOL com-
parisons will be restricted to late effects. Genitourinary (GU) and 
gastrointestinal (GI) toxicities were measured using the Common 
Terminology Criteria for Adverse Events Version 3 (CTCAE v3) 
during the acute period (≤3 months) and the Radiation Therapy 
Oncology Group (RTOG) late radiation morbidity schema for 
late effects (>3  months). Toxicities were assessed at baseline, 
weekly during treatment (only weeks 3 and 5 in study 2), at 
months 3 and 6, and every 6 months thereafter. PSA was assessed 
at baseline, months 3 and 6, and every 6 months. Follow-up for all 
QOL and toxicity endpoints continued for 5 years; biochemical 
and survival outcomes continued annually until the patient was 
discharged from follow-up.
TaBlE 1 | Patient characteristics.
Study 1 (35 Gy/5 F) 
N = 84
Study 2 (40 Gy/5 F) 
N = 30
p-Value
Median age (IQR), years 67 (61–71) 68 (65–73) 0.27
Clinical stage 0.78
 T1a-c 78 (92.9%) 27 (90.0%)
 T2a 6 (7.1%) 3 (10.0%)
Median PSA at baseline 
(IQR), ng/mL
5.3 (4.2–7.3) 4.7 (3.5–7.5) 0.33
Gleason score <0.0001
 6 84 (100.0%) 18 (60.0%)
 7 0 (0%) 12 (40.0%)
Risk group (ProCaRS) (12) <0.0001
 Low risk 84 (100%) 18 (60.0%)
 Low-intermediate risk 0 (0%) 11 (36.7%)
 High-intermediate risk 0 (0%) 1 (3.3%)
Median TRUS prostate 
volume (IQR), mL
37 (29–55) 40 (31–53) 0.62
Median IPSS score (IQR) 5 (3–9) 5 (3–11) 0.66
IQR, interquartile range; IPSS, International Prostate Symptom Score; TRUS, 
transrectal ultrasound.
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Statistical analysis
Patient characteristics were summarized as median and inter-
quartile range (IQR) for continuous variables, and proportions 
for categorical variables. The EPIC scores were calculated as 
mean ± SD and graphically presented as mean (with 95% con-
fidence intervals) over time. A minimum clinically important 
change (MCIC) was defined as a decrease in QOL from baseline 
to follow-up, which exceeded half of the SD of that value at base-
line (10). The “average EPIC change” was calculated by (mean 
of EPIC scores from month 6 to 60 – baseline score) while the 
“worst EPIC score” was calculated by (lowest of EPIC scores from 
month 6 to 60 – baseline score). These metrics were chosen to 
identify the average change in QOL as well as the maximum peak 
change in QOL, respectively. Actual, non-imputed data were used 
for analysis. Waterfall plots were created using changes in EPIC 
scores. In addition, to assess more severe changes in QOL, we 
compared the proportion of patients with 1 and 2 SD of change. 
Fisher’s exact test was used to compare categorical data between 
studies, including proportion of patients experiencing MCIC and 
proportion with moderate/big problems in specific EPIC items. 
Wilcoxon rank-sum test was used to compare continuous data. 
Two-sided p-value <0.05 was considered statistically significant. 
Generalized estimating equations methodology was used to 
account for repeated measurements and the impact of covariates 
on trends in EPIC scores over time (11), with binomial distribu-
tion and logit link function. All analyses were conducted using 
Statistical Analysis Software (SAS version 9.4 for Windows).
rESUlTS
A total of 114 patients were included. There were 84 patients 
from study 1 and 30 from study 2 with median QOL follow-up 
of 56 months (IQR 46–60) and 38 months (IQR 32–42), respec-
tively. Overall completion of EPIC questionnaires at 36 months 
was 70/95 (73.7%). Patient characteristics are described in 
Table 1 and were balanced between the groups with respect to 
age, clinical stage, baseline PSA, prostate volume, and baseline 
IPSS. Neoadjuvant ADT was given to one patient in study 1 and 
none in study 2. However, owing to different study eligibility 
criteria, there was a greater proportion of patients with Gleason 
6 adenocarcinoma (100 vs. 60%, p < 0.0001) and Prostate Cancer 
Risk Stratification (ProCaRS) (12) low-risk disease (100 vs. 60%, 
p < 0.0001) in study 1.
Baseline QOL data are shown in Data Sheet 1. There were no 
statistically significant differences in baseline EPIC summary 
domain scores between the two groups. However, there was a 
lower mean urinary function score in study 1 compared to study 
2 (90.4 vs. 95.0%, p < 0.001).
The proportion of patients with average and worst changes in 
EPIC QOL score, which were clinically significant from months 
6–60, are shown in Table 2. No statistically significant differences 
were found between treatment groups. MCIC was reported in 
average EPIC scores in 19.5 vs. 24.1% for urinary QOL (p = 0.60), 
26.8 vs. 41.4% for bowel QOL (p = 0.16), and 42.9 vs. 38.5% in 
sexual QOL (p = 0.82) for the 35 and 40 Gy groups, respectively. 
When examining the worst change in EPIC QOL score, 67.1 vs. 
58.6% had a urinary MCIC (p = 0.50), 65.9 vs. 62.1% had a MCIC 
in bowel score (p = 0.82), and 64.9 vs. 50.0% (p = 0.24) had MCIC 
in sexual QOL for study 1 and 2. Using additional cutoff values of 
1 and 2 SD of baseline value to compare the proportion of patients 
with moderate or large changes in average QOL did not identify 
any significant differences (Data Sheet 2).
Waterfall plots of the average change in EPIC urinary, bowel, 
and sexual scores are shown in Figure 1.
analysis of QOl Over Time
Mean EPIC urinary, bowel, and sexual scores over time are shown 
in Figure 2. The QOL scores are fairly stable over time, and no 
significant differences exist between treatment groups at any 
time point, with the exception of lower bowel QOL for patients 
in study 2 at 6 (p = 0.06) and 12 months (p = 0.04) after treatment.
Longitudinal analysis of risk of MCIC in QOL by treatment 
group after adjustment for time is shown in Table 3. There was no 
significant time trend in MCIC of QOL scores with the exception 
of the sexual domain, in which there was an increasing risk of 
MCIC in sexual scores over time (OR 1.02, 95% CI 1.01–1.04, 
p < 0.001). This indicates a 2% increased risk of MCIC in sexual 
score per month. Treatment group was not significantly associ-
ated with MCIC in any of the QOL domains.
The impact of baseline covariates on QOL scores was con-
ducted while adjusting for time and treatment group. Analysis of 
urinary MCIC included the following covariates: baseline urinary 
QOL score (p = 0.01), age (years) (p = 0.18), clinical stage (T1a-c 
vs. T2a) (p = 0.63), log prostate volume (p = 0.73), Gleason score 
(6 vs. 7) (p = 0.21), log baseline PSA (p = 0.18), and log IPSS 
(p = 0.49). Only baseline urinary QOL score had a statistically 
significant effect (OR 1.05, 95% CI 1.01–1.10, p = 0.01), indicating 
that patients with higher baseline urinary score were at increased 
risk for MCIC. There was no significant interaction among the 
covariates.
Similarly, analysis of factors affecting bowel QOL included: 
baseline bowel QOL score (p =  0.18), age (years) (p =  0.84), 
TaBlE 2 | Proportion of patients with minimum clinically important change (MCiC)a in EPiC quality-of-life scores by treatment group.
average change Worst change
Summary domain Study 1 (35 Gy/5 F) Study 2 (40 Gy/5 F) p-Value Study 1 (35 Gy/5 F) Study 2 (40 Gy/5 F) p-Value
Urinary 0.60 0.50
 No MCIC 66 (80.5%) 22 (75.9%) 27 (32.9%) 12 (41.4%)
 MCIC 16 (19.5%) 7 (24.1%) 55 (67.1%) 17 (58.6%)
Bowel 0.16 0.82
 No MCIC 60 (73.2%) 17 (58.6%) 28 (34.2%) 11 (37.9%)
 MCIC 22 (26.8%) 12 (41.4%) 54 (65.9%) 18 (62.1%)
Sexual 0.82 0.24
 No MCIC 44 (57.1%) 16 (61.5%) 27 (35.1%) 13 (50.0%)
 MCIC 33 (42.9%) 10 (38.5%) 50 (64.9%) 13 (50.0%)
QOL, quality of life; EPIC, Expanded prostate cancer index composite.
aMinimum clinically important change defined as a decrease in quality of life from baseline to follow-up which exceeds half of the standard deviation of the baseline value (10).
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(15). No differences were found in the other bowel-related, uri-
nary, or sexual QOL. Also, in a detailed analysis of GI outcomes 
from the UK RT01 randomized trial comparing 64 vs. 74  Gy, 
QOL assessment using the University of Los Angeles Prostate 
Cancer Index showed no differences in diarrhea, bowel distress, 
or bowel problems (16). However, there was an increased risk 
of moderate abdominal pain (HR 1.53, 95% CI 1.13–2.06) and 
severe rectal urgency (HR 1.64, 95% CI 1.11–2.42) observed with 
higher dose.
Many studies have reported on QOL outcomes after prostate 
SBRT (5, 17), but few have compared such data with respect to 
the effect of increasing dose. The previously mentioned dose-
escalation study of 45, 47.5, and 50 Gy in five fractions was not 
powered to compare QOL outcomes between treatment arms (5). 
However, comparison of QOL measured by the EPIC instrument 
did not identify any difference in bowel QOL between the 45 and 
50  Gy arms (p =  0.5), but there was significantly worse bowel 
QOL for the 47.5 Gy dose level (p = 0.01). No differences were 
found in urinary QOL between the three dose levels.
In a separate analysis of physician-rated toxicities from the 
present study, dose-escalated SBRT was associated with greater 
risk of grade 2+, but not grade 3+, toxicities (7). Other studies 
have found similar associations between higher SBRT dose and 
toxicities (18), and there are several possible explanations for 
why it did not result in worse patient-reported outcomes (19), 
in the present study. First, the increase in biologically effective 
dose to OAR is dependent upon the alpha–beta ratio. For the 
rectum, the alpha–beta ratio for grade≥2 late toxicity has been 
estimated to be 4.8 Gy, but with a wide 68% CI ranging from 0.6 
to 46 Gy (20). The corresponding difference between dose levels 
in the present study in equivalent 2 Gy fractions would be 14.6 Gy 
(68% CI 6.4–30.0), but may be as low as 6.4 Gy, if the alpha–beta 
ratio for bowel QOL is similar to that for late toxicity. Second, 
the relationship between dose and QOL outcomes has not been 
well characterized, and differences in dose at 35 to 40 Gy may not 
be expected to result in significant changes in QOL (i.e., on the 
“flat” segment of the dose-complication curve). Third, although 
this study used the validated EPIC instrument and commonly 
reported threshold of one-half SD (10) to identify a MCIC, it 
may not have been sensitive enough to detect small changes in 
QOL. Finally, patients who received higher dose may have had 
clinical stage (T1a-c vs. T2a) (p =  0.13), log prostate volume 
(0.41), Gleason score (6 vs. 7) (p = 0.02), and log baseline PSA 
(p = 0.55). Only Gleason score was significant (OR 0.23, 95% CI 
0.07–0.81, p = 0.02), with patients with Gleason 7 having lower 
risk of MCIC in bowel score compared to Gleason 6.
Severity of QOl impairment
Patients were asked “Overall, how big a problem has your (urinary 
function/bowel habits/sexual function) been for you during the 
last 4 weeks?” with answers dichotomized into no problem/very 
small problem/small problem vs. moderate problem/big problem. 
Results are listed in Table 4. There were no significant differences 
between the two studies at baseline or last follow-up. Few (<4%) 
patients reported moderate/severe problems in overall urinary 
function or bowel habits at last follow-up in both studies.
DiSCUSSiOn
This is one of the first studies to examine the effect of dose-
escalation in prostate SBRT on QOL endpoints. The results show 
that when increasing the dose from 35 to 40 Gy, delivered in five 
fractions once per week, there is no significant difference in long-
term QOL outcomes. Unique features of this analysis include 
prospective data collection and longer follow-up.
The results of the present study should be compared to existing 
literature within the context of differences in treatment technique 
and total dose. There is conflicting data regarding the impact of 
conventionally fractionated, dose-escalated radiotherapy on 
QOL endpoints using older radiation techniques (13–16). In 
the Proton Radiation Oncology Group 9509 randomized study 
of 70.2 vs. 79.2 Gy, there were no differences in urinary, bowel, 
or sexual outcomes using the Prostate Cancer Symptom Indices 
assessed at a median 9.4 years (13). Similarly, in the GETUG-06 
trial of 70 vs. 80 Gy, there were no differences in QOL using the 
European Organization for Research and Treatment of Cancer 
(EORTC) QOL Questionnaire and prostate-specific module (14).
In contrast, other studies have shown detriment in specific 
patient-reported outcomes after dose-escalated radiotherapy. In 
the MD Anderson randomized trial of 70 vs. 78 Gy, there was a 
significant increase in frequency of bowel movements associated 
with high-dose radiotherapy at 3 years after treatment (p = 0.03) 
FiGUrE 1 | average change in EPiC (a) urinary (B) bowel and (C) sexual quality-of-life scores. Negative and positive changes reflect worse and better QOL 
after treatment, respectively. Horizontal dotted, dashed, and straight lines indicate 0.5, 1, and 2 SD of the baseline score.
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FiGUrE 2 | Mean scores (and 95% confidence intervals) for (a) urinary (B) bowel (C) and sexual EPiC quality-of-life domains over time.
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TaBlE 3 | longitudinal analysis of EPiC quality of life by treatment group.
Or 95% Ci p-Value
Urinary MCIC
 Time (months) 0.99 0.97–1.01 0.23
 Treatment group (study 1 vs. 2) 0.98 0.54–1.79 0.95
Bowel MCIC
 Time (months) 1.00 0.99–1.02 0.99
 Treatment group (study 1 vs. 2) 0.61 0.31–1.20 0.15
Sexual MCIC
 Time (months) 1.02 1.01–1.04 <0.001
 Treatment group (study 1 vs. 2) 1.18 0.54–2.59 0.68
OR, odds ratio; CI, confidence interval; MCIC, minimum clinically important change.
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worse treatment-related toxicity, but adapted to the effects of 
altered function, and not reported any impairment on the QOL 
questionnaires (21).
The QOL outcomes reported in this study are similar to those 
reported by other groups. In a multi-institutional study of 864 
patients treated with prostate SBRT to a median dose of 36.25 Gy 
in four or five fractions (17), EPIC scores were similar to the 
present study with long-term urinary, bowel, and sexual scores 
of 80–90, 85–95, and 20–50. Although 20–40% of patients in our 
study reported a change in long-term QOL, which was clinically 
detectable, the majority of changes were mild to moderate in 
severity. This is a limitation of the MCIC definition in that it does 
not distinguish minimal from severe changes in QOL.
To assess severe problems in QOL, we also analyzed specific 
EPIC items, which asked about overall patient function. The pro-
portion of patients who reported moderate or severe problems in 
overall urinary function or bowel habits was <4% at both dose 
levels, which is reassuring. Also while 25% of patients experienced 
moderate or severe problems in sexual function at last follow-up, 
this is similar to values observed at baseline.
We analyzed the effect of patient, tumor, and treatment-related 
factors to identify variables associated with worse post-treatment 
QOL. Only a higher baseline urinary QOL score was associated 
with greater risk of clinically significant change in QOL after 
treatment. This finding is similar to other QOL studies in which 
patients with greater current function have more potential for loss 
of function, compared to patients with intermediate or poor base-
line function (22). Gleason 7 was also found to be associated with 
greater risk of MCIC in bowel QOL. The reason for this is unclear 
and requires further investigation, but may be a type I error.
Limitations of our study should be noted. As QOL was not 
assessed in study 1 during the first 3 months after treatment, acute 
changes in QOL could not be compared. Also, the smaller sample 
size of patients receiving 40 Gy limited the power to detect small 
differences between study groups. We have completed accrual to 
a multicentre, phase 2 randomized trial of 40 Gy in five fractions, 
delivered every other day vs. once weekly (23). One hundred 
fifty-two patients had acute and late QOL measured, and we will 
report these data as they mature. Finally, radiotherapy planning 
was different between the two cohorts. CTV volumes were based 
on CT and MRI for patients receiving 40 Gy, whereas it was based 
on CT only imaging for those treated with 35 Gy. Offset against 
this, the PTV margin was 5 mm for the 40 Gy study and 4 mm for 
the 35 Gy study. Compared to CT-based planning, MRI-defined 
prostate volumes are 21–30% (24–26) smaller, which has been 
shown to reduce rectal and bladder doses (26). However, these 
dosimetric advantages have only translated into reduced urinary, 
but not rectal, toxicity in reports with clinical outcomes (24, 
26). No studies have compared QOL endpoints with MRI vs. 
CT-based planning.
COnClUSiOn
Increased dose for prostate SBRT from 35 to 40 Gy, delivered in 
five once-weekly fractions, was not associated with a clinically 
significant difference in late QOL outcomes. Long-term effects 
on urinary and bowel QOL remain mild to moderate, with most 
patients reporting the same QOL scores in late follow-up com-
pared to baseline.
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TaBlE 4 | Overall problematic nature of quality-of-life domains at 
baseline and last follow-up.
Baseline N (%) last follow-up N (%)
Study 1 Study 2 p* Study 1 Study 2 p*
Urinary function 0.39 0.98
No/very small/
small problem
77 (95.1) 27 (90.0) 81 (96.4) 28 (96.6)
Moderate/ 
severe problem
4 (4.9) 3 (10.0) 3 (3.6) 1 (3.5)
Bowel habits 0.45 0.98
No/very small/
small problem
80 (98.8) 28 (96.6) 81 (96.4) 28 (96.6)
Moderate/ 
severe problem
1 (1.2) 1 (3.5) 3 (3.6) 1 (3.5)
Sexual function 0.91 0.92
No/very small/
small problem
60 (76.9) 22 (75.9) 60 (74.1) 21 (75.0)
Moderate/ 
severe problem
18 (23.1) 7 (24.1) 21 (25.9) 7 (25.0)
*Comparison between study 1 and study 2.
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